CONMED Corp. Stock
Price
Target price
?
?
0.930%
0.4
0.930%
€41.46
08:10 / Frankfurt
WKN: 886793 / Symbol: CNMD / Name: CONMED / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
CONMED Corp. Stock
The CONMED Corp. stock is trending slightly upwards today, with an increase of €0.40 (0.930%) compared to yesterday's price.
Currently there is a rather positive sentiment for CONMED Corp. with 3 Buy predictions and 1 Sell predictions.
On the other hand, the target price of 41 € is below the current price of 43.6 € for CONMED Corp., so the potential is actually -5.96%.
So far the community has only identified positive things for CONMED Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of CONMED Corp. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | 0.930% | 16.062% | 52.381% | -0.444% | 28.000% | -56.078% | -60.000% |
| Haemonetics Corp. | 1.340% | 7.092% | 14.394% | - | 10.219% | - | - |
| Bio-Rad Labs Inc. A | 3.260% | 4.601% | 11.494% | 18.149% | 12.834% | -20.881% | -53.810% |
| Penumbra Inc | -0.070% | -0.214% | 1.083% | 34.940% | 5.105% | 22.807% | 25.224% |
Comments
CONMED (CNMD) had its "underperform" rating reaffirmed by Bank of America Corporation. They now have a $40.00 price target on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
News
CONMED Q2 Earnings Call Highlights
Key Points
- Interested in CONMED Corporation? Here are five stocks we like better.
- CONMED delivered better-than-expected Q2 results: Organic sales rose 6%, adjusted EPS increased 20% to $1.38
